Green Cross’(www.greeencross.com) Hunterase is gaining attention in the field of cure for rare diseases where multinational pharmaceutical firms dominate. Hunterase breaks the monopoly market to become the world’s second successful cure for Hunter syndrome in 2012.
On February 23, Green Cross(President &CEO Huh, Eun Chul) announced that it received ‘New Treatment Award’ in the 11th Annual Lysosomal Disease Network WORLD Symposium held in Orlando, Florida from Feb. 9 to Feb. 13.
‘New Treatment Award’ is the award to be given to the medicine which makes great contribution to lysosomal diseases every year. It is considered unconventional that Hunterase was given the award before its launching in North America.
Lysosomal dieases develop in general when there is a lack of specific enzyme in lysosome, including Hunter syndrome, Gaucher disease, Fabry disease and Pompe's disease. The patients with these lysosomal diseases are treated with medicines enabling enzyme replacement therapy (ERT).
“The award was given since Hunterase is highly recommended for its superiority and contribution for enhancing the quality of life among those patients with lysosomal diseases,” said an official of Green Cross, “Doctors and groups of patients across the world are very interested in Hunterase.”
By Lee Jae-seung
